Antegren uses a different mechanism than is found in current MS drugs. Another study showed the drug helped reduce bowel inflammation in Crohn's disease sufferers. It's also a potential treatment for ulcerative colitis and rheumatoid arthritis, says Subrata Ghosh, a gastroenterologist at Imperial ...
Official answer by Drugs.com Migraine Treatment The newest novel drug (approved March 9, 2023) for the treatment of migraine is Zavzpret (zavegepant) nasal spray. Migraine Prevention The newest drug (approved September 28, 2021) for the prevention of migraine is Qulipta (atogepant). New...
In this review, we sort out the progress in the treatment of DKD in recent years, the research status of some emerging drugs, and the potential drugs for the treatment of DKD in the future, hoping to provide some directions for clinical treatment of DKD. Graphical Abstract The drugs ...
Discontinuation of treatment is recommended in the following situations: when a patient is taking drugs with associated risks, such as anticoagulation agents for conditions like atrial fibrillation, deep vein thrombosis, or pulmonary embolism; or when any of the following conditions occur: a hyper...
Treatment: New drugs help battleNo abstract is available for this article.doi:10.1002/scin.5591611016NoneScience News
There are manydrugsapproved to treat MS. But Krupp said some recent studies are showing that patients fare better long term when they get "high-efficacy" medications — which include anti-CD20 antibodies — versus olderdrugswith more-moderate effects. ...
their clinical use. Non-invasive approaches like intranasal administration, P-glycoprotein (P-gp) inhibition, pro-drugs, and carrier/targeted nanocarrier-aided delivery systems (alone or often in combination) hold positive clinical prospects for brain targeting if explored further in the right direction...
we briefly summarize key efficacy and tolerability data. We classify the degree of innovation as first-in-indication, i.e., drugs for the treatment of a condition for which no approved medical treatments existed; first-in-class, i.e., drugs with a molecular mechanism of action that had not...
in assessing the drug is that the full results of the trial haven't yet been shared publicly or published in a peer-review journal.We cannot access the full data or examine the trial yet,and there is always a motivation for private companies to overstate the effectiveness o...
Over the past decade, Schering-Plough Corp.'s Claritin brand of allergy drugs have reaped about $9 billion in total worldwide revenue. It's no wonder, then, that the company would do whatever it takes to keep the franchise on its best-selling medicine go